medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2023, Number 4

<< Back Next >>

Acta Med 2023; 21 (4)

Impact of Roux-en-Y gastric bypass as a treatment for gastroesophageal reflux in patients with obesity in a tertiary center

Medina MMA, Medina GS, Maldonado PDG, Angélica MVM, Romano BLA, Vences ADA, Alvarado DJ, Castillo GFA

Language: Spanish
References: 30
Page: 356-362
PDF size: 204.03 Kb.


ABSTRACT

Introduction: obesity is the main modifiable risk factor for the development of chronic diseases, including gastroesophageal reflux (GER). Mexico is the country with the highest prevalence of overweight in Latin America (43.9%). GER affects one third of the general population, and up to 70% of patients with obesity. The Roux-Y gastric bypass (RYGB) has proven to be highly effective in patients with severe obesity and GER, with 97% remission of symptoms. This study seeks to demonstrate the impact that RYGB has on GER in obese patients who do not respond to conventional treatment. Material and methods: retrospective, observational, analytical study based on clinical records of patients with obesity and GER undergoing RYGB. Results: 84 patients with GER and obesity were studied, obtaining a clinical remission of 89.7% (p < 0.001), a decrease in the degree of esophagitis by endoscopic finding (p < 0.001) and reflux through the esophagogram (p < 0.039) after a year of RYGB. Conclusion: RYGB is a useful tool in the treatment of GER in patients with obesity refractory to conventional treatment, with clinical remission of symptoms.


REFERENCES

  1. Astrup A, Dyerberg J, Selleck M, Stender S. Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes Rev. 2008; 9 Suppl 1: 48-52.

  2. Clark JM, Brancati FL. The challenge of obesity-related chronic diseases. J Gen Intern Med. 2000; 15 (11): 828-829.

  3. Emerging Risk Factors Collaboration; Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377 (9771): 1085-1095.

  4. World Health Organization. World health statistics 2017: monitoring health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2017.

  5. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007; 85 (9): 660-667.

  6. World Health Organization. Obesity, preventing and managing the global epidemic–report of a WHO consultation on obesity. Geneva: WHO; 1997.

  7. Secretaría de Salud. Norma Oficial Mexicana NOM-043-SSA2-2005, Servicios básicos de salud. Promoción y educación para la salud en materia alimentaria. Criterios para brindar orientación. México: Diario Oficial de la Federación; 2006.

  8. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101 (8): 1900-1920; quiz 1943.

  9. Bajwa SA, Toro F, Kasi A. Physiology, esophagus. Treasure Island (FL): StatPearls; 2021.

  10. Roman S, Holloway R, Keller J, Herbella F, Zerbib F, Xiao Y, et al. Validation of criteria for the definition of transient lower esophageal sphincter relaxations using high-resolution manometry. Neurogastroenterol Motil. 2017; 29 (2). doi: 10.1111/nmo.12920.

  11. Mittal RK, Karstens A, Leslie E, Babaei A, Bhargava V. Ambulatory high-resolution manometry, lower esophageal sphincter lift and transient lower esophageal sphincter relaxation. Neurogastroenterol Motil. 2012; 24 (1): 40-46, e2.

  12. Suter M, Dorta G, Giusti V, Calmes JM. Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients. Obes Surg. 2004; 1 4(7): 959-966.

  13. Pandolfino JE, Kim H, Ghosh SK, Clarke JO, Zhang Q, Kahrilas PJ. High-resolution manometry of the EGJ: an analysis of crural diaphragm function in GERD. Am J Gastroenterol. 2007; 102 (5): 1056-1063.

  14. Varela JE, Hinojosa M, Nguyen N. Correlations between intra-abdominal pressure and obesity-related co-morbidities. Surg Obes Relat Dis. 2009; 5 (5): 524-528.

  15. Lambert DM, Marceau S, Forse RA. Intra-abdominal pressure in the morbidly obese. Obes Surg. 2005; 15 (9): 1225-1232.

  16. Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016; 14 (2): 175-82.e1-3.

  17. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005; 54 (1): 11-17.

  18. Becker V, Grotz S, Schlag C, Nennstiel S, Beitz A, Haller B et al. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol. 2014; 20 (14): 4017-4024.

  19. Broeders JA, Mauritz FA, Ahmed Ali U, Draaisma WA, Ruurda JP, Gooszen HG et al. Systematic review and meta-analysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal reflux disease. Br J Surg. 2010; 97 (9): 1318-1330.

  20. Andreou A, Watson DI, Mavridis D, Francis NK, Antoniou SA. Assessing the efficacy and safety of laparoscopic antireflux procedures for the management of gastroesophageal reflux disease: a systematic review with network meta-analysis. Surg Endosc. 2020; 34 (2): 510-520.

  21. Abdelrahman T, Latif A, Chan DS, Jones H, Farag M, Lewis WG et al. Outcomes after laparoscopic anti-reflux surgery related to obesity: A systematic review and meta-analysis. Int J Surg. 2018; 51: 76-82.

  22. Tekin K, Toydemir T, Yerdel MA. Is laparoscopic antireflux surgery safe and effective in obese patients? Surg Endosc. 2012; 26 (1): 86-95.

  23. Smith SC, Edwards CB, Goodman GN. Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en-Y gastric bypass. Obes Surg. 1997; 7 (6): 479-484.

  24. Frezza EE, Ikramuddin S, Gourash W, Rakitt T, Kingston A, Luketich J et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002; 16 (7): 1027-1031.

  25. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 2015; 44 (2): 203-231.

  26. Nau P, Jackson HT, Aryaie A, Ibele A, Shouhed D, Lo Menzo E, et al. Surgical management of gastroesophageal reflux disease in the obese patient. Surg Endosc. 2020; 34 (1): 450-457.

  27. Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Mazzini G, Pereira Mda S. The impact of gastric bypass on gastroesophageal reflux disease in morbidly obese patients. Ann Surg. 2016; 263 (1): 110-116.

  28. Goonawardena J, Ward S. Effect of Roux-en-Y gastric bypass on Barrett's esophagus: a systematic review. Surg Obes Relat Dis. 2021; 17 (1): 221-230.

  29. Tai CM, Lee YC, Wu MS, Chang CY, Lee CT, Huang CK, et al. The effect of Roux-en-Y gastric bypass on gastroesophageal reflux disease in morbidly obese Chinese patients. Obes Surg. 2009; 19 (5): 565-570.

  30. Manuel Moreno G. Definición y clasificación de la obesidad. Rev Med Clin Condes 2012; 23 (2): 124-128.




2020     |     www.medigraphic.com